Kinetic considerations for the quantitative assessment of efflux activity and inhibition: Implications for understanding and predicting the effects of efflux inhibition

被引:85
作者
Kalvass, J. Cory
Pollack, Gary M.
机构
[1] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Div Drug Delivery & Disposit, Sch Pharm, Chapel Hill, NC 27599 USA
关键词
absorption; blood-brain barrier; breast cancer resistance protein (BCRP); Caco-2; efflux inhibition; efflux ratio; efflux transporters; MDCK; multidrug resistance; P-glycoprotein; transcellular flux;
D O I
10.1007/s11095-006-9135-x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Unexpected and complex experimental observations related to efflux transport have been reported in the literature. This work was conducted to develop relationships for efflux activity (PSefflux) as a function of commonly studied kinetic parameters [permeability-surface area product (PS), efflux ratio (ER), degree of efflux inhibition (phi(i)), 50% inhibitory concentration (IC50), and Michaelis-Menten constant (K-m)]. Methods. A three-compartment model (apical, cellular, and basolateral) was used to derive flux equations relating the initial rate of flux and steady-state mass transfer in the presence or absence of active efflux. Various definitions of efflux ratio (ER) were examined in terms of permeability-surface area products. The efflux activity (PSefflux) was expressed in terms of ER and PS. The relationships between PSefflux and PS, ER, phi(i), IC50, and K-m were solved mathematically. Simulations and examples from the literature were used to illustrate the resulting mathematical relationships. Results. The relationships derived according to a three-compartment model differed fundamentally from commonly accepted approaches for determining PSefflux, phi(i), IC50 and K-m. Based on the model assumptions and mathematical derivations, currently used mathematical relationships erroneously imply that efflux activity is proportional to change in PS (i.e., flux or P-app) and thus underestimate PSefflux and phi(i,) and overestimate IC50 and K-m. Conclusions. An understanding of the relationship between efflux inhibition and kinetic parameters is critical for appropriate data interpretation, standardization in calculating and expressing the influence of efflux transport, and predicting the clinical significance of efflux inhibition.
引用
收藏
页码:265 / 276
页数:12
相关论文
共 31 条
  • [1] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein
    Adachi, Y
    Suzuki, H
    Sugiyama, Y
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (12) : 1660 - 1668
  • [2] Balakrishnan A, 2005, J CLIN PHARMACOL, V45, P1087
  • [3] Many P-glycoprotein substrates do not inhibit the transport process across cell membranes
    Barecki-Roach, M
    Wang, EJ
    Johnson, WW
    [J]. XENOBIOTICA, 2003, 33 (02) : 131 - 140
  • [4] Compound profiling for p-glycoprotein at the blood-brain barrier using a microplate screening system
    Bauer, B
    Miller, DS
    Fricker, G
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (08) : 1170 - 1176
  • [5] The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km
    Bentz, J
    Tran, TT
    Polli, JW
    Ayrton, A
    Ellens, H
    [J]. PHARMACEUTICAL RESEARCH, 2005, 22 (10) : 1667 - 1677
  • [6] Utility of mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development
    Chen, CP
    Liu, XR
    Smith, BJ
    [J]. CURRENT DRUG METABOLISM, 2003, 4 (04) : 272 - 291
  • [7] Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic Prodrugs across the blood-brain barrier using an in situ perfused rat brain model
    Chen, WQ
    Yang, JZ
    Andersen, R
    Nielsen, LH
    Borchardt, RT
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (02) : 849 - 857
  • [8] Variable modulation of opioid brain uptake by P-glycoprotein in mice
    Dagenais, C
    Graff, CL
    Pollack, GM
    [J]. BIOCHEMICAL PHARMACOLOGY, 2004, 67 (02) : 269 - 276
  • [9] Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds
    Dagenais, C
    Zong, J
    Ducharme, J
    Pollack, GM
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (07) : 957 - 963
  • [10] Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
    Doan, KMM
    Humphreys, JE
    Webster, LO
    Wring, SA
    Shampine, LJ
    Serabjit-Singh, CJ
    Adkison, KK
    Polli, JW
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) : 1029 - 1037